Sign In
Buy AVTE
$2.68
+0 (+0%)
At Close: Jul 25, 2025
Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights
08:00am, Monday, 14'th Aug 2023
WALTHAM, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the live
Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
05:00pm, Tuesday, 11'th Jul 2023
WALTHAM, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives
Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference
08:00am, Thursday, 01'st Jun 2023
WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives
Aerovate: Small Mid-Stage Biotech Targeting Multibillion-Dollar PAH Market
08:45am, Wednesday, 12'th Apr 2023
AVTE reported Q4 2023 earnings in line with expectations and has enough cash runway until H2 2025. AV-101, AVTE's lead asset, is on track with patient enrollment in phase 2b PAH trial, and top-line Ph
Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference
08:00am, Thursday, 02'nd Mar 2023
WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the live
Aerovate: Developing An Exciting PAH Drug, Initiating With A Buy
07:12am, Sunday, 29'th Jan 2023
Aerovate is a SMID-cap biotech developing an inhaled imatinib for pulmonary arterial hypertension. AV-101's Phase 2b PAH data is expected in 4Q 2023 or 1Q 2024, which we believe will be positive.
AVTE Stock Increases On High Volume
05:27pm, Monday, 18'th Oct 2021
The stock price of Aerovate Therapeutics Inc (NASDAQ: AVTE) increased by over 19% today. These are some details you should know.
Aerovate Therapeutics Announces Its Addition to the Russell 2000® Index
08:00am, Friday, 17'th Sep 2021
WALTHAM, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the liv
The 5 biggest insider stock buys of last week
11:08am, Monday, 12'th Jul 2021
Here are the five companies that saw the biggest combined stock purchases from insiders during the week ended July 9.
BOSTON, July 02, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of pati
Drug Formulation Developer Aerovate Therapeutics Kick Starts Trading Today With Upsized Debut
03:37pm, Wednesday, 30'th Jun 2021
Just shy of a full year after emerging from stealth mode, Aerovate Therapeutics Inc (NASDAQ: AVTE) is listing onto NASDAQ with an upsized offering. The company priced 8.68 million shares at $14, th
Aerovate Therapeutics Announces Pricing of Upsized Initial Public Offering
10:59pm, Tuesday, 29'th Jun 2021
BOSTON, June 29, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of pati
Aerovate Therapeutics Readies $100 Million IPO Effort
08:00pm, Monday, 28'th Jun 2021
Aerovate Therapeutics has filed to raise $100 million in a U.S. IPO. The firm is developing a treatment for pulmonary arterial hypertension.
